Product
CD19CAR T-cells
1 clinical trial
1 indication
Indication
Primary CNS LymphomaClinical trial
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01